A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT02613208
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab will be administered as per local clinical practice and local labeling.
  • Paclitaxel — DRUG
    Paclitaxel will be administered as per local clinical practice and local labeling.

Study Details

This multicenter, observational, prospective study will identify a powerful and easy predictive/prognostic marker to use with participants under bevacizumab.

Key Dates

First listed
Nov 24, 2015
Start date
Dec 9, 2015
Status verified
Feb 2020
Primary completion
Dec 3, 2018
Completion
Dec 3, 2018

Study Design

Enrollment
111 participants (actual)

Arms

  • Arm: Participants With Metastatic Breast Cancer
    Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.

Primary Outcome Measure

Percentage of Participants With Clinical Benefit [ Time Frame: During follow-up (up to 18 months) ]

Related Studies